Page last updated: 2024-10-15

kinamycin f

Description

kinamycin F: isolated from Streptomyces murayamaensis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135618571
CHEBI ID48215
MeSH IDM0164332

Synonyms (8)

Synonym
CHEBI:48215
50556-18-8
kinamycin f
(1r,2s,3r,4s)-11-diazo-1,2,3,4,9-pentahydroxy-2-methyl-2,3,4,11-tetrahydro-1h-benzo[b]fluorene-5,10-dione
5h-benzo(b)carbazole-5-carbonitrile, 1,2,3,4,6,11-hexahydro-1,2,3,4,7-pentahydroxy-3-methyl-6,11-dioxo-, (1alpha,2beta,3alpha,4alpha)-
Q27121103
DTXSID00964779
11-diazonio-1,2,3,4,9-pentahydroxy-2-methyl-10-oxo-2,3,4,10-tetrahydro-1h-benzo[b]fluoren-5-olate

Research Excerpts

Overview

Kinamycin F is a bacterial metabolite which contains an unusual and potentially reactive diazo group. It is known for its ability to inhibit cell growth.

ExcerptReference
"Kinamycin F is a bacterial metabolite which contains an unusual and potentially reactive diazo group that is known for its ability to inhibit cell growth. "( Cell Cycle Arrest and Apoptosis Induced by Kinamycin F in Human Osteosarcoma Cells.
Bavelloni, A; Blalock, W; Errani, C; Faenza, I; Focaccia, E; Piazzi, M, 2017
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
kinamycin
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's1 (8.33)18.2507
2000's3 (25.00)29.6817
2010's7 (58.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]